The winners of the XPRIZE will move on to collaborate with OpenCovidScreen, a non-profit founded by scientists and business leaders, to drive needed innovation through “Open Science.”

Modification to ‘reasonable and necessary’ definition in MCIT final rule offers new avenue for drug manufacturers to get products covered in Part B. The Biden Administration will have to decide whether it will keep the Trump regulation unchanged.

Japan's latest batch of new drug approvals includes the country's second CAR-T therapy, along with multiple oncology drugs and a novel migraine treatments, which should all reach the market in the next few months following reimbursement price listing. 

Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.